Cipher Pharmaceuticals ( (TSE:CPH) ) has issued an update.
Cipher Pharmaceuticals reported significant financial growth in 2024, with total revenue increasing by 58% to $33.4 million, driven by the acquisition of Natroba and strong performance of Epuris. The acquisition of Natroba has provided Cipher with a U.S. commercial footprint, enhancing its growth strategy and cash flow generation, supported by a new credit facility with the National Bank of Canada.
More about Cipher Pharmaceuticals
Cipher Pharmaceuticals is a company in the pharmaceutical industry, focusing on dermatology and infectious disease products. Its primary products include Epuris, a leading product in Canada, and Natroba, which was recently acquired to expand its U.S. market presence.
YTD Price Performance: -19.63%
Average Trading Volume: 16,713
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $203.3M
Find detailed analytics on CPH stock on TipRanks’ Stock Analysis page.